Alterity Therapeutics (PRNAD) Equity Average (2020 - 2021)

Alterity Therapeutics (PRNAD) posted quarterly Equity Average of $5.8 million for Q2 2019, down 4.74% on a QoQ basis from $6.1 million in Q4 2018.

Alterity Therapeutics (PRNAD) Equity Average (2020 - 2021) Analysis & Trends

Alterity Therapeutics (PRNAD) has reported Equity Average for 2 consecutive years, with $5.8 million the latest figure, recorded in Q2 2019.

In Q2 2019, Equity Average changed N/A year-over-year to $5.8 million; the TTM figure through Jun 2019 stood at $5.8 million (changed N/A YoY), while the FY2023 annual figure was $20.5 million, down 15.48% from the prior year.
Equity Average came in at $5.8 million for Q2 2019 at Alterity Therapeutics, down from $6.1 million in the prior quarter.
The five-year high for Equity Average was $6.1 million in Q4 2018, with the low at $5.8 million in Q2 2019.

Download Data

Date	Value
Jun 30, 2021	753.98 Mn
Dec 31, 2020	744.59 Mn